Breast Cancer (Clinical Trial)

Patients Sought for Trial of Anti-Angiogenesis Drug

Published in Women's Health Weekly, May 18th, 1998

Patients with metastatic breast cancer, who meet specific eligibility requirements, are being sought for participation in a large multicenter clinical trial to evaluate Marimastat, an angiogenesis inhibitor.

The study is being conducted by the Eastern Cooperative Oncology Group (ECOG), a cancer clinical trials Cooperative Group supported by the National Cancer Institute. The study is taking place at over 170 ECOG member institutions in the United States and seeks to enroll 334 patients.

Breast cancer is the most common type of cancer in women in the U.S. Metastatic cancer most commonly involves the bones, lung, liver, lymph nodes, and skin.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1998-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry